Dark

MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close

May 13, 2025 3:59:30 PM EDT

295.41USD-1.779%(-5.35)288,140

295.00Bid 300.26Ask 5.26Spread

Pre-market

May 13, 2025 8:48:30 AM EDT

300.25USD-0.170%(-0.51)414

After-hours

May 13, 2025 4:00:30 PM EDT

295.36USD-0.017%(-0.05)478

Overview

Options

Historical

Exchanges

Shorts

News

Jan 31, 2022

07:05AM EST Madrigal Pharmaceuticals Announces Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom Was Safe, Well-Tolerated And Provided Statistically Significant Improvements In Key Measures Of Liver And Cardiovascular Health Benzinga

07:00AM EST Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: GlobeNewswire Inc

Jan 30, 2022

04:02PM EST Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st at 7:00 AM ET Benzinga

04:00PM EST Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022. GlobeNewswire Inc

Jan 10, 2022

08:00AM EST Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer. GlobeNewswire Inc

Dec 30, 2021

08:05AM EST Madrigal Provides Update On Timeline For Topline Results From The Phase 3 MAESTRO-NAFLD-1 Clinical Trial Of Resmetirom Benzinga

08:00AM EST Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease, presumed NASH. GlobeNewswire Inc

Nov 23, 2021

07:00AM EST Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Nov 12, 2021

08:18AM EST Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:14AM EST Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:00AM EST Positive Resmetirom Data from Completed Open-Label Portion of GlobeNewswire Inc

Nov 4, 2021

06:53AM EDT Madrigal Pharmaceuticals Q3 EPS $(3.79) Down From $(3.75) YoY Benzinga

06:50AM EDT Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results. GlobeNewswire Inc

Oct 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

05:04AM EDT Jefferies Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $151 Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 4, 2021

06:50AM EDT Madrigal Pharmaceuticals Announces Support of Fatty Liver GlobeNewswire Inc

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 9, 2021

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

11:23AM EDT HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $170 Benzinga

Aug 5, 2021

07:01AM EDT Madrigal Pharmaceuticals Q2 EPS $(3.72) Down From $(3.18) YoY Benzinga

06:50AM EDT Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. GlobeNewswire Inc

Aug 2, 2021

06:50AM EDT Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

05:49PM EDT Madrigal Pharmaceuticals Offers Patients Resmetirom In Planned Open Label Active Treatment Extension Of Phase 3 MAESTRO-NAFLD-1 Clinical Study Benzinga

05:48PM EDT Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned GlobeNewswire Inc

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

06:51AM EDT Madrigal Pharmaceuticals Completes Enrollment Of 52 Week Liver Biopsy Patient Population In Phase 3 MAESTRO-NASH Study Of Resmetirom Benzinga

06:50AM EDT Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver GlobeNewswire Inc

Jun 25, 2021

11:30AM EDT Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress 2021 Benzinga

11:30AM EDT Madrigal Pharmaceuticals Announces Presentation of Positive GlobeNewswire Inc

Jun 8, 2021

06:50AM EDT Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

May 24, 2021

06:39AM EDT NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect? Benzinga

May 21, 2021

09:38AM EDT Madrigal Pharmaceuticals to Participate in UBS Global Healthcare GlobeNewswire Inc

May 18, 2021

09:00AM EDT Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual GlobeNewswire Inc

07:14AM EDT Madrigal Pharma Names Alex Howarth CFO RTTNews

06:50AM EDT Madrigal Pharmaceuticals Appoints Alex Howarth Chief Financial Officer Benzinga

06:50AM EDT Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Alex Howarth has joined Madrigal as Chief Financial Officer. GlobeNewswire Inc

May 17, 2021

10:13AM EDT Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $193 Benzinga

May 6, 2021

07:05AM EDT Madrigal Pharmaceuticals Q1 EPS $(3.32) Down From $(2.34) YoY Benzinga

06:50AM EDT Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. GlobeNewswire Inc

Apr 30, 2021

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 28, 2021

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

Feb 26, 2021

05:17AM EST Chardan Capital Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $203 Benzinga

Feb 25, 2021

06:54AM EST Madrigal Pharmaceuticals Q4 EPS $(3.82) Down From $(1.80) YoY Benzinga

06:50AM EST Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. GlobeNewswire Inc

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Nov 24, 2020

08:59AM EST Evercore ISI Group Reinstates Outperform on Madrigal Pharmaceuticals, Announces $180 Price Target Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

06:51AM EST Madrigal Pharma To Presented Oral Presentation On Phase 3 MAESTRO-NAFLD-1 Trial Today At 4:30 p.m. EST At Liver Meeting Digital Experience Benzinga

06:50AM EST Madrigal Pharmaceuticals Highlights Presentations at The Liver GlobeNewswire Inc

Nov 12, 2020

10:08AM EST Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $177 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

08:19AM EST 10 Biggest Price Target Changes For Friday Benzinga

07:13AM EST BMO Capital Maintains Market Perform on Madrigal Pharmaceuticals, Raises Price Target to $124 Benzinga

06:48AM EST HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $184 Benzinga

Nov 5, 2020

09:26AM EST Madrigal Pharma Filing Shows Registration For $200M Common Stock Shelf Offering Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

06:55AM EST Madrigal Pharmaceuticals Q3 EPS $(3.75) Down From $(1.39) YoY Benzinga

06:50AM EST Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. GlobeNewswire Inc

Oct 1, 2020

08:06AM EDT Madrigal Pharmaceuticals Announces Three Abstracts Accepted By The Liver Meeting Digital Experience Including Positive Data From Ongoing Open Label Arm Of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial Benzinga

08:00AM EDT Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The GlobeNewswire Inc

Sep 3, 2020

06:54AM EDT Madrigal Pharma Reports Exceeded Target Enrollment For Phase 3 MAESTRO NAFLD-1 Trial Benzinga

06:50AM EDT Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 GlobeNewswire Inc

Aug 26, 2020

06:52AM EDT Madrigal To Present Secondary Analyses Of Data From Phase 2 NASH Study Of Resmetirom RTTNews

06:50AM EDT Madrigal Pharmaceuticals to Present Secondary Analyses of Data GlobeNewswire Inc

Aug 6, 2020

08:20AM EDT Madrigal Pharmaceuticals Q2 EPS $(3.18) Down From $(1.28) YoY Benzinga

06:50AM EDT Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: GlobeNewswire Inc